Capital Flow Monitor · Sponsors · CIK 1641241
Cyrus Biotechnology, Inc.
3005 1ST AVE, SEATTLE, WA, 98121 · 2062586561
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$3.0M
Sold
$1.5M
% sold
49.4%
Investors
17
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-05-08 | D/A ·current | 506(b) | $3.0M | $1.5M | 49.4% | 17 | EDGAR ↗ |
| 2025-07-16 | D | 506(b) | $1.5M | $1.1M | 74.0% | 12 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Lucas Nivon — Executive Officer / Director, SEATTLE, WA
- Mark Benjamin — Executive Officer, SEATTLE, WA
- Yifan Song — Director, SEATTLE, WA
- Chad Waite — Director, SEATTLE, WA
- Anthony Manning — Director, SEATTLE, WA
- Ramakrishna Satyavolu — Director, SEATTLE, WA
-
Jason Smith — Director, SEATTLE, WA
9 other raises
- TFC Big Gulps Mustang, LLC $700K of $700K · 100.0%
- TFC Desert Color, LLC $350K of $350K · 100.0%
- Optimeos Life Sciences, Inc. $1.0M of $2.0M · 50.0%
- SponsorCX, Inc. $4.1M of $5.0M · 82.8%
- TFC Westminster Oil 2 LLC $445K of $445K · 100.0%
- TFC Syracuse Big Gulps LLC $850K of $850K · 100.0%
- TFC Zaragoza KC LLC $750K of $750K · 100.0%
- TFC Belle Creek LLC $375K of $375K · 100.0%
- TFC Big Gulps LLC $730K of $730K · 100.0%
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.